Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes: Major role of CYP3A

Biochemical Pharmacology

Volumn 53, Issue 8, 1997, Pages 1187-1195

  Chiba, Masato ^a   Hensleigh, Michelle ^a   Lin, Jiunn H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CYP3A2; CYP3A4; HIV protease inhibitor; intestinal metabolism; oxidation

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEXAMETHASONE; INDINAVIR; OXYGENASE; PROTEINASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TESTOSTERONE;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG METABOLISM; DRUG OXIDATION; FIRST PASS EFFECT; HUMAN; HUMAN TISSUE; INTESTINE; KINETICS; LIVER METABOLISM; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; JEJUNUM; KINETICS; MALE; MICROSOMES; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030908131     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00100-7     Document Type: Article

References (22)

1. Kaminsky LS and Fasco MJ, Small intestinal cytochrome P450. Crit Rev Toxicol 21: 407-422, 1992.
2. Zhang Q-Y, Wikoff J, Dunbar D and Kaminsky L, Characterization of rat small intestinal cytochrome P-450 composition and inducibility. Drug Metab Dispos 24: 322-328, 1996.
3. de Waziers I, Cugnenc PH, Yang CS, Leroux J-P and Beaune PH, Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extra-hepatic tissues. J Pharmocol Exp Ther 253: 387-394, 1990.
4. Kolars JC, Schmiedlin-Ren P, Dobbins WO III, Schuetz J, Wrighton SA and Watkins PB, Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology 102: 1186-1198, 1992.
5. Hebert MF, Roberts JP, Prueksaritanont T and Benet LZ, Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52: 453-457, 1992.
6. Paine MF, Shen DD, Kunze KL, Perkins JD and Thurmmel KE, Intestinal metabolism of midazolam by the anhepatic transplant patient. ISSX Proc 8: 298, 1995.
7. Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Darke PL, Zugay J, Quintero JC, Blahy OM, Roth E, Sardana VV, Schlabach AJ, Graham PI, Condra JH, Gotlib L, Holloway MK, Lin JH, Chen I-W, Vastag K, Ostovic D, Anderson PS, Emini EA and Huff JR, L-735,524: An orally bio-available human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA 91: 4096-4100, 1994.
8. Lin JH, Chen I-W, Vastag KJ and Ostovic D, pH-Dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab Dispos 23: 730-735, 1995.
9. Lin JH, Chiba M, Balani SK, Chen I-W, Kwei GY-S, Vastag KJ and Nishime JA, Species differences in the pharmacokinetics and metabolism of indinavir, a potent HIV protease inhibitor. Drug Metab Dispos 24: 1111-1120, 1996.
10. Omura T and Sato R, The carbon-monoxide binding pigment of liver microsomes. J Biol Chem 239: 2370-2378, 1964.
11. Bonkovsky HL, Hauri H-P, Marti U, Gasser R and Meyer UA, Cytochrome P450 of small intestinal epithelial cells: Immunochemical characterization of the increase in cytochrome P450 caused by phenobarbital. Gastroenterology 88: 458-467, 1985.
12. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurement with the Polin phenol reagent. J Biol Chem 193: 265-275, 1951.
13. Borm P, Frankhuijzen-Sierevogel A and Noordhoek J, Time and dose dependence of 3-methylcholanthrene-induced metabolism in rat intestinal mucosal cells and microsomes. Biochem Pharmacol 31: 3707-3710, 1982.
14. Houston JB, Utility of in vitro drug metabolism data in prediction of in vivo metabolic clearance. Biochem Pharmacol 47: 1469-1479, 1994.
15. Boxenbaum H, Interspecies variation in liver weight, hepatic blood flow and antipyrine intrinsic clearance in extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 8: 165-176, 1980.
16. Gerlowski LE and Jain RK, Physiologically based pharmacokinetic modeling: Principles and applications. J Pharma Sci 72: 1103-1127, 1983.
17. Pang KS and Rowland M, Hepatic clearance of drugs. I. Theoretical consideration of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular activity on hepatic drug clearance. J Pharmacokinet Biopharm 5: 625-653, 1977.
18. Klippert P, Borm P and Noordhoek J, Prediction of intestinal first-pass effect of phenacetin in the rat from enzyme kinetic data - Correlation with in vivo data using mucosal blood flow. Biochem Pharmacol 31: 2545-2548, 1982.
19. Bohlen HG, Henrich H, Gore RW and Johnson PC, Intestinal muscle and mucosal blood flow during direct sympathetic stimulation. Am J Physiol 235: H40-H45, 1978.
20. Balani SK, Arison BH, Mathai L, Kauffman L, Miller RR, Stearns RA, Chen I-W and Lin JH, Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos 23: 266-270, 1995.
21. Chiba M, Hensleigh M, Nishime JA, Balani SK and Lin JH, Role of cytochrome P-450 3A4 in human metabolism of MK-639, a potent HIV protease inhibitor. Drug Metab Dispos 24: 307-314, 1996.
22. Guengerich FP and Shimada T, Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4: 391-407, 1991.